ORGANIC LETTERS

2006
Vol. 8, No. 10
2071−2073

Asymmetric, *anti*-Selective Scandium-Catalyzed Sakurai Additions to Glyoxyamide. Applications to the Syntheses of *N*-Boc D-Alloisoleucine and D-Isoleucine

David A. Evans,* Yimon Aye, and Jimmy Wu

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138

evans@chemistry.harvard.edu

Received February 24, 2006

ABSTRACT



An enantio- and diastereoselective Sakurai–Hosomi reaction, catalyzed by chiral scandium pyridyl-bis(oxazoline) (pybox) complexes, has been developed. Both alkyl- and aryl-substituted allylsilanes are effective coupling partners with *N*-phenylglyoxamide. Applications of this reaction to the asymmetric syntheses of *N*-Boc D-alloisoleucine and D-isoleucine are described.

In this communication we report our results on the use of the chiral scandium complex **1** as an effective catalyst for the enantioselective Sakurai−Hosomi[1] addition of terminally substituted allylsilanes to *N*-phenylglyoxamide (**2**). This reaction furnishes "ene-type" products with *anti* diastereoselection and is therefore complementary to our recently reported *syn*-selective, scandium-catalyzed glyoxamide-ene reactions.[2] These crystalline enantiopure adducts are versatile chiral building blocks for β-substituted α-hydroxy and α-amino acids.

The synthesis of homoallylic alcohols through the nucleophilic allylation of aldehydes and ketones continues to be a powerful transformation.[3] The first catalytic enantioselective variant using a chiral (acyloxy)borane (CAB) complex was reported by Yamamoto.[4] Subsequently, Keck and others have reported the use of various Lewis acidic metals and BINOL/BINAP-based chiral ligands in promoting asymmetric allylations.[5] The corresponding Lewis base catalyzed reactions have also been reported by Denmark and others.[6]

(1) Hosomi, A.; Sakurai, H. *Tetrahedron Lett.* **1976**, *16*, 1295.
(2) Evans, D. A.; Wu, J. *J. Am. Chem. Soc.* **2005**, *127*, 8006.
(3) For general reviews on diastereoselective allylation/crotylation reactions, see: Denmark, S. E.; Fu, J. *Chem. Rev.* **2003**, *103*, 2763 and references therein.
(4) Furuta, K.; Mouri, M.; Yamamoto, H. *Synlett* **1991**, 561.

10.1021/ol0604771 CCC: $33.50
Published on Web 04/18/2006

Optimization studies using (*E*)-crotyltrimethylsilane demonstrated that reactions carried out at −20 °C with 10 mol % catalyst afforded good enantioselection (95% ee) and *anti* diastereoselection (26:1) (Table 1, entry 1). Under these conditions, allylation of unbranched (*E*) alkyl-substituted silanes afforded the expected products in good yields and excellent enantio- and diastereoselectivities (entries 3 and 4). (*Z*)-Crotyltrimethylsilane was also evaluated under the same conditions, affording the *syn* product with excellent enantioselectivity (94%) and moderate *syn* diastereoselectivity (4:1) (entry 2). The complementary stereoselectivity of (*E*) and (*Z*) geometrical isomers displayed in entries 1 and 2 is noteworthy because the Lewis acid promoted Sakurai−Hosomi reaction, which proceeds via an open transition state, is known to be stereoconvergent with respect to olefin geometry.[3,6b] Our qualitative observations indicate that the pybox ligand architecture seems to impart significant levels of diastereocontrol to these addition reactions.

Table 1. Scope of Sc(III)-Catalyzed Sakurai−Hosomi Additions



entry[a]	R[b]	cat. loading	*T* (°C)	% ee[c]	*anti*/*syn*	% yield[g]	mp (°C)
1	Me	10 mol %	−20	95	26:1[e]	89	104
2	(*Z*)-Me	10 mol %	−20	94	1:4[f]	76	90
3	Et	10 mol %	−20	91	32:1	76	50
4	*n*-Pr	10 mol %	−20	93[d]	29:1	71	59
5	Ph	15 mol %	rt	99[d]	99:1[e]	67	127
6	4-Me-Ph	15 mol %	rt	99	99:1	75	146
7	4-MeO−Ph	15 mol %	rt	97	99:1[e]	64	135
8	4-F−Ph	15 mol %	rt	99	99:1	73	151
9	2-Me-Ph	15 mol %	rt	99	9:1[e]	64	89
10	*β*-Nap	15 mol %	rt	97	99:1	89	160

[a] All reactions were run overnight at the indicated temperatures. [b] 8.5 equiv of allylsilane was used; however, the unreacted portion could be recovered and reused without loss of selectivity. [c] Enantiomeric excesses were determined by HPLC using Chiracel OD-H, AD-H, or Whelk-(*S*) columns. [d] Absolute stereochemistry was determined by Mosher's ester analysis. Remaining product configurations were assigned by analogy. [e] *anti* stereochemistry confirmed by X-ray analysis. [f] *syn* stereochemistry confirmed by X-ray analysis. [g] Isolated yields.

The preliminary investigations into the reactivity of aryl-substituted allylsilanes revealed that higher temperatures (room temperature) and catalyst loadings are required. Under these conditions, aryl-substituted allylsilanes are generally observed to be more selective than their alkyl-substituted counterparts.[7] Importantly, substrates containing either electron-withdrawing or electron-donating substituents in the *para* position are effective coupling partners (entries 7 and 8). Nucleophiles with substituents in the *ortho* position as well as *β*-naphthylallylsilane are also tolerated (entries 9 and 10). An added benefit of using *N*-phenylglyoxamide (**2**) as an electrophile is that all of the desired products are routinely isolated as crystalline solids with well-defined melting points (Table 1). In addition, we were able to show that the *N*-phenylamide functionality can be conveniently converted into its carboxylic acid derivative in high yield. TBS protection of the alcohol followed by *N*-Boc activation of the amide and subsequent hydrolysis[8] afforded the expected carboxylic acid in 98% yield over three steps (Scheme 1).

Scheme 1. *N*-Phenylamide Hydrolysis



We anticipated that this enantioselective addition reaction could serve as a stereodivergent route to *β*-substituted α-amino acids. Because of its medicinal importance, D-alloisoleucine was identified as a relevant synthesis target. This amino acid is of interest due to its presence in biologically important depsipeptides.[9] and has been used as a chiral precursor for syntheses of isostatins,[10] oxytocin analogues,[11] and other natural cytotoxic depsipeptides.[9,12] As a consequence, a number of syntheses of this molecule have been reported.[13] In the following discussion, we report the Lewis acid mediated catalytic enantio- and diastereoselective route to D-alloisoleucine as well as its C(3)-epimer, the common amino acid D-isoleucine. The enantioselective step in each case involves the Sc-catalyzed allylation using (*E*)- and (*Z*)-crotyltrimethylsilanes, **3** and **9**, respectively (Schemes 2 and 3).

The conversion of the C(2)-hydroxy group in **4** to the required C(2)-amino functionality was accomplished in a

(5) (a) Keck, G. E.; Tarbet, K. H.; Geraci, L. S. *J Am. Chem. Soc*. **1993**, *115*, 8467. (b) Costa, A. L.; Piazza, M. G.; Tagliavini, E.; Umani-Ronchi, A. *J. Am. Chem. Soc*. **1993**, *115*, 7001. (c) Gauthier, D. R.; Carreira, E. M. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 2363. (d) Yanagisawa, A.; Kageyama, H.; Nakatsuka, Y.; Asakawa, K.; Matsumoto, Y.; Yamamoto, H. *Angew. Chem., Int. Ed.* **1999**, *38*, 3701. (e) Yamasaki, S.; Fujii, K.; Wada, R.; Kanai, M.; Shibasaki, M. *J. Am. Chem. Soc.* **2002**, *124*, 6536. (f) Wadamoto, M.; Ozasa, N.; Yanagisawa, A.; Yamamoto, H. *J. Org. Chem.* **2003**, *68*, 5593. (g) Wadamoto, M.; Yamamoto, H. *J. Am. Chem. Soc.* **2005**, *127*, 14556.

(6) (a) Denmark, S. E.; Coe, D. M.; Pratt, N. E.; Griedel, B. D. *J. Org. Chem.* **1994**, *59*, 6161. (b) Denmark, S. E.; Fu, J. *J. Am. Chem. Soc*. **2001**, *123*, 9488. (c) Iseki, K.; Kuroki, Y.; Takahashi, M.; Kishimoto, S.; Kobayashi, Y. *Tetrahedron* **1997**, *53*, 3513. (d) Malkov, A. V.; Orsini, M.; Pernazza, D.; Muir, K. W.; Langer, V.; Meghani, P.; Kocovsky, P. *Org. Lett.* **2002**, *4*, 1047. (e) Malkov, A. V.; Dufková, Farrugia, L.; Kocovsky, P. *Angew. Chem., Int. Ed.* **2003**, 3674. For a general review on Lewis base catalyzed allylation reactions, see: Denmark, S. E.; Fu, J. *Chem. Commun.* **2003**, 167.

(7) During these studies, we developed efficient routes for the synthesis of *γ*-alkyl- and *γ*-aryl-substituted allylsilanes. See Supporting Information.

(8) Evans, D. A.; Britton, T. C.; Ellman, J. A. *Tetrahedron Lett*. **1987**, *28*, 6141.

(9) (a) Bodanzky, M.; Perlman, D. *Science* **1969**, *163*, 352. (b) Li, S.; Dumdei, E. J.; Blunt, J. W.; Munro, M. H. G.; Robinson, W. T.; Pannell, L. K. *J. Nat. Prod*. **1998**, *61*, 724.

(10) (a) Liang, B.; Portonovo, P. S.; Vera, M. D.; Xiao, D.; Joullie, M., M. *Org. Lett*. **1999**, *1*, 1319. (b) Rinehart, S.; Sakai, R.; Kishore, V.; Sullins, D. W.; Li, K. *J. Org. Chem*. **1992**, *57*, 3007. (c) Rinehart, K. L.; Kishore, V.; Nagarajan, S.; Gloer, R. J.; Bozich, F. A.; Li, K.-M.; Maleczka, R. E.; Todsen, W. L.; Munro, M. H., G.; Sullins, D. W.; Sakai, R. *J. Am. Chem. Soc*. **1987**, *109*, 6846.

(11) Flouret, G.; du Vigneaud, V. *J. Am. Chem. Soc*. **1965**, *87*, 3775.

(12) Kogen, H.; Kiho, T.; Makayama, M.; Furukawa, Y.; Kinoshita, T.; Inukai, M. *J. Am. Chem. Soc*. **2000**, *122*, 10214.

(13) Ogawa, C.; Sugiura, M.; Kobayashi, S. *Angew. Chem., Int. Ed*. **2004**, *43*, 6491 and references therein.

two-step procedure. Adduct **4** was subjected to 2.0 equiv of $MeSO_2Cl$ and Et_3N (CH_2Cl_2, rt, 36 h) to afford the derived α-mesyloxyamide in high yield. The unpurified intermediate was treated with 1.1 equiv of NaN_3 in (DMF, 70 °C, 48 h), yielding the α-azido amide **5** without the need for flash chromatography in 95% yield over the two steps, with complete inversion of configuration at C(2). It is noteworthy that either raising the reaction temperature or increasing the amount of NaN_3 in an attempt to achieve a faster reaction rate led to product epimerization.

Catalytic hydrogenation of unpurified **5** (H_2 1 atm, Pd/C, EtOH, rt, 5 h) effected hydrogenation of both the azide and the olefinic moieties, affording the corresponding saturated C(2)-primary amine, which was subsequently treated with 5 equiv of Boc_2O and 2 equiv of DMAP[14] in an optimized solvent mixture of 1:9 CH_2Cl_2/MeCN (rt, 1 h) to furnish the product of mono-Boc protection of the primary amine, with consequential Boc protection of the *N*-phenylamide, bis-Boc-protected **6**. Peroxide-mediated hydrolysis[8] of **6** provided *N*-Boc D-alloisoleucine **7** in quantitative yield (Scheme 2) with an overall yield of 70%.

Scheme 2. Synthesis of *N*-Boc D-Alloisoleucine



Synthesis of C(3)-epimeric enantioenriched *N*-Boc D-isoleucine **8** was undertaken starting from the common precursor glyoxamide **2** using the alternative nucleophile (*Z*)-crotyltrimethylsilane **9**. Analogous transformations as previously described subsequently furnished enantio- and diastereopure *N*-Boc D-isoleucine **8** in 60% overall yield (Scheme 3).

Scheme 3. Synthesis of *N*-Boc D-Isoleucine



In summary, we have developed an asymmetric, *anti*-selective Sakurai−Hosomi reaction promoted by [Sc(S,S)-Phpybox](OTf)$_3$ complex **1**. Good generality was demonstrated as both aliphatic and aromatic allylsilanes are effective nucleophiles in additions to the glyoxamide **2**. This reaction was applied to the straightforward enantioselective syntheses of *N*-Boc D-alloisoleucine **7** and D-isoleucine **8** from a common starting material, glyoxamide **2**. Within the syntheses delineated above, all except two of the intermediates are highly crystalline solids, making both routes applicable to large-scale preparations.

Acknowledgment. This research was supported by grants from the National Science Foundation and the NIH (GM-33328-21). J.W. thanks the ASEE for an NDSEG predoctoral Fellowship and the ACS for a Division of Organic Chemistry Graduate Fellowship. Y.A. gratefully acknowledges Eli Lilly for a Lilly Graduate Fellowship.

Supporting Information Available: Experimental procedures, characterization data, and NMR spectra for all new compounds and for the syntheses of **7** and **8**. Crystallographic data and structures (CIF). This material is available free of charge via the Internet at http://pubs.acs.org.

OL0604771

(14) Evans, D. A.; Fitch, D. M.; Smith, T. E.; Cee, V. J. *J. Am. Chem. Soc.* **2000**, *122*, 10033.